Expertise in
8
conditions

Dr. Ann E. Woolfrey

Pediatric Hematology Oncology
825 Eastlake Ave E, 
Seattle, WA 
Clinical Trials:Currently Recruiting for 2 Trials
Expertise in
8
conditions
825 Eastlake Ave E, 
Seattle, WA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ann Woolfrey is a Pediatric Hematologist Oncology provider in Seattle, Washington. Dr. Woolfrey is highly rated in 8 conditions, according to our data. Her top areas of expertise are Aplastic Anemia, Fanconi Anemia, Congenital Aplastic Anemia, Graft Versus Host Disease (GvHD), and Bone Marrow Transplant.

Her clinical research consists of co-authoring 67 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pediatric Hematology Oncology
Licenses
Pediatric Hematology-Oncology in WA
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

PacificSource
  • PPO

Locations

825 Eastlake Ave E, Seattle, WA 98109

Additional Areas of Focus

Dr. Woolfrey has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
Enrollment Status: Recruiting
Publish Date: April 17, 2025
Intervention Type: Drug
A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units Manufactured by the National Cord Blood Program and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients
A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units Manufactured by the National Cord Blood Program and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients
Enrollment Status: Recruiting
Publish Date: April 19, 2024
Intervention Type: Biological
Study Phase: Phase 2
Selection of Allogeneic Hematopoietic Cell Donors Based on KIR and HLA Genotypes
Selection of Allogeneic Hematopoietic Cell Donors Based on KIR and HLA Genotypes
Enrollment Status: Active_not_recruiting
Publish Date: June 29, 2025
Intervention Type: Genetic
Study Phase: Not Applicable
A Study Evaluating BPX-501 T Cells and AP1903 for Prevention of Graft Versus Host Disease (GVHD) After Haploidentical, Related, T Cell-Depleted Hematopoietic Cell Transplantation for Non-Malignant Diseases
A Study Evaluating BPX-501 T Cells and AP1903 for Prevention of Graft Versus Host Disease (GVHD) After Haploidentical, Related, T Cell-Depleted Hematopoietic Cell Transplantation for Non-Malignant Diseases
Enrollment Status: Terminated
Publish Date: March 25, 2024
Intervention Type: Biological
Study Drugs: BPX-501, Rimiducid
Study Phase: Phase 1
Phase I/II Study of CaspaCIDe T Cells (BPX-501; Rivogenlecleucel) From an HLA Partially Matched Family Donor After Negative Selection of TCRαβ+ T Cells in Paediatric Patients Affected by Haematological Disorders
Phase I/II Study of CaspaCIDe T Cells (BPX-501; Rivogenlecleucel) From an HLA Partially Matched Family Donor After Negative Selection of TCRαβ+ T Cells in Paediatric Patients Affected by Haematological Disorders
Enrollment Status: Terminated
Publish Date: September 29, 2023
Intervention Type: Biological, Drug
Study Drugs: Rivogenlecleucel, Rimiducid
Study Phase: Phase 1/Phase 2
Phase I/II Study of CaspaCIDe® T Cells From an HLA-Partially Matched Family Donor After Negative Selection of TCR αβ+T Cells in Pediatric Patients Affected by Hematological Disorders
Phase I/II Study of CaspaCIDe® T Cells From an HLA-Partially Matched Family Donor After Negative Selection of TCR αβ+T Cells in Pediatric Patients Affected by Hematological Disorders
Enrollment Status: Active_not_recruiting
Publish Date: July 12, 2022
Intervention Type: Biological, Drug
Study Drugs: BPX-501 T Cells, Rimiducid
Study Phase: Phase 1/Phase 2
A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant
A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant
Enrollment Status: Completed
Publish Date: March 02, 2022
Intervention Type: Other, Drug
Study Phase: Phase 3
A Clinical Trial of Gene-Modified Stem Cells to Generate HIV-Resistant Cells in Conjunction With Standard Chemotherapy for Treatment of Lymphoma in Patients With HIV Infection
A Clinical Trial of Gene-Modified Stem Cells to Generate HIV-Resistant Cells in Conjunction With Standard Chemotherapy for Treatment of Lymphoma in Patients With HIV Infection
Enrollment Status: Withdrawn
Publish Date: November 20, 2018
Intervention Type: Biological, Drug, Other
Study Phase: Phase 1
Human Immunodeficiency Virus (HIV)-Specific Immune Reconstitution After Hematopoietic Cell Transplant for Treatment of Hematologic Malignancy in Patients Infected With HIV
Human Immunodeficiency Virus (HIV)-Specific Immune Reconstitution After Hematopoietic Cell Transplant for Treatment of Hematologic Malignancy in Patients Infected With HIV
Enrollment Status: Completed
Publish Date: May 24, 2017
Intervention Type: Other, Procedure
Study Phase: Phase 2
View 7 Less Clinical Trials

67 Total Publications

Comparison of outcomes of HCT in blast phase of BCR-ABL1- MPN with de novo AML and with AML following MDS.
Comparison of outcomes of HCT in blast phase of BCR-ABL1- MPN with de novo AML and with AML following MDS.
Journal: Blood advances
Published: June 11, 2020
Similar Doctors
Expertise in
16
conditions
Dr. Douglas S. Hawkins
Pediatric Hematology Oncology
Expertise in
16
conditions
Dr. Douglas S. Hawkins
Pediatric Hematology Oncology
4800 Sand Point Way Ne, 
Seattle, WA 
 (3.3 miles away)
206-987-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Douglas Hawkins is a Pediatric Hematologist Oncology provider in Seattle, Washington. Dr. Hawkins is highly rated in 16 conditions, according to our data. His top areas of expertise are Rhabdomyosarcoma, Adult Soft Tissue Sarcoma, Osteosarcoma, Osteotomy, and Bone Marrow Aspiration.

Expertise in
21
conditions
Dr. Sarah S. Leary
Pediatric Hematology Oncology
Expertise in
21
conditions
Dr. Sarah S. Leary
Pediatric Hematology Oncology
4800 Sand Point Way Ne, Mailstop B-6553, 
Seattle, WA 
 (3.3 miles away)
206-987-2106
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sarah Leary is a Pediatric Hematologist Oncology provider in Seattle, Washington. Dr. Leary is highly rated in 21 conditions, according to our data. Her top areas of expertise are Medulloblastoma, Glioma, Embryonal Tumor with Multilayered Rosettes, Diffuse Midline Glioma H3 K27M-Mutant, and Bone Marrow Aspiration.

Expertise in
7
conditions
Dr. James M. Olson
Pediatric Hematology Oncology
Expertise in
7
conditions
Dr. James M. Olson
Pediatric Hematology Oncology
4800 Sand Point Way Ne, 
Seattle, WA 
 (3.3 miles away)
206-987-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

James Olson is a Pediatric Hematologist Oncology provider in Seattle, Washington. Dr. Olson is highly rated in 7 conditions, according to our data. His top areas of expertise are Medulloblastoma, Embryonal Tumor with Multilayered Rosettes, Glioma, and Diffuse Midline Glioma H3 K27M-Mutant.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Woolfrey's expertise for a condition
ConditionClose
    View All 16 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile